Your daily dose of the clinical news you may have missed.
Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.
The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.
Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.
Findings suggest that optimizing care for children with hypertension may reduce the risk of adult CVD, report researchers.
Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.
Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.
Your daily dose of the clinical news you may have missed.
Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.